Antiplatelet Drugs Prevent The Formation Of Blood Clots As They Alter Platelet Activation And Aggregation In Response To Endothelial Injury
Platelets are blood cells that clump together to form a blood clot in case of an injury or cut. They also clump together inside a blood vessel that is damaged or has a buildup of plaque. Blood clots can lead to a heart attack or stroke. Antiplatelet Drugs help to prevent blood clots from forming. They are often prescribed after a heart attack or in case of a disease that increases the risk of having blood clots.
A doctor may prescribe aspirin, clopidogrel, prasugrel or ticagrelor to stop blood clots from forming. Medication for treating an existing heart condition or other illness while taking drugs can also be prescribed. These medications are called concomitant therapies. They work differently and are given at different times during the day. Aspirin and warfarin are often prescribed together, as they act on different parts of the clotting process.
Aspirin reduces the risk of having another heart attack. Antiplatelet Drugs can cause unwanted side effects, such as a sore stomach or bleeding problems. A doctor should be informed in case of any side effects, especially if they are severe. Antiplatelet medicines are usually taken as pills that can be swallowed. They can also be given in a vein, if there is trouble swallowing tablets.
Drugs alter platelet activation and aggregation in response to endothelial injury, a crucial step in arterial thrombosis. Oral medications are broadly classified as irreversible cyclooxygenase inhibitors, ADP receptor inhibitors, adenosine reuptake inhibitors, glycoprotein IIb/IIIa platelet inhibitors, or phosphodiesterase inhibitors. The latter two agents inhibit the breakdown of cyclic AMP on platelets to reduce cytoplasmic second messengers that stimulate thromboxane release.
The Antiplatelet Drugs Market is anticipated to reach US$ 2,153.4 million in 2022 and is predicted to grow at a CAGR of 7.8% from 2022 to 2030.
Glycoprotein IIb/IIIa platelet inhibitors prevent the binding of fibrinogen and von Willebrand factor to the platelet glycoprotein IIb/IIIa receptor on activated platelets, thereby decreasing platelet aggregation and clot formation. These drugs are commonly used in ACS patients who undergo PCI.
A new class of drugs, called direct thrombin inhibitors, directly bind to and block the action of thrombin without the use of an antiplatelet agent. Examples of these drugs are recombinant hirudins (bivalirudin, argatroban), dabigatran (Dabigatran) and apixaban (Edoxaban). Antiplatelet therapy can be disrupted by major bleeding in patients on these medications. In most cases, resumption of antiplatelet therapy is not recommended after major bleeding.
Bayer’s oral Factor Xia inhibitor Asundexian, gained Fast Track designation from the the United States Food and Drug Administration in February 20222. It is an anticoagulant used for treating arterial and venous thrombosis.

Comments
Post a Comment